Treatment and management of FXTAS

Elizabeth Berry-Kravis, Deborah A. Hall, Maureen A. Leehey, Randi J Hagerman

Research output: Chapter in Book/Report/Conference proceedingChapter

8 Scopus citations


Fragile X-associated tremor/ataxia syndrome (FXTAS) affects older adult carriers of the FMR1 premutation and can be associated with a broad array of clinical symptoms and presentations including tremor, ataxia, parkinsonism, executive function disturbance and dementia, psychiatric symptoms of anxiety, depression and disinhibition, peripheral neuropathy, autonomic dysfunction, hormonal dysfunction, and pain syndromes. Although controlled trials have not been carried out in individuals with FXTAS, there is information available regarding symptomatic treatments. Treatment is generally supportive, directed at component symptoms that are most problematic, and makes use of evidence regarding effectiveness of medications and other interventions for treatment of disorders that have phenotypic overlap with FXTAS. This chapter summarizes available treatments and supports that can be helpful for persons with FXTAS.

Original languageEnglish (US)
Title of host publicationThe Fragile X-Associated Tremor Ataxia Syndrome (FXTAS)
PublisherSpringer New York
Number of pages18
ISBN (Print)9781441958051, 9781441958044
StatePublished - 2010

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'Treatment and management of FXTAS'. Together they form a unique fingerprint.

Cite this